2. Academic Validation
  3. Development of Benzimidazole-Based BZ-30 as an Orally Bioavailable Broad-Spectrum Inhibitor of SARS-CoV-2

Development of Benzimidazole-Based BZ-30 as an Orally Bioavailable Broad-Spectrum Inhibitor of SARS-CoV-2

  • J Med Chem. 2026 Apr 23;69(8):9537-9557. doi: 10.1021/acs.jmedchem.6c00365.
Simran Kaur 1 2,  Deshkanwar S Brar 1,  Akshay Joshi 3,  Nittu Singh 3,  Ravneet S Chawla 3,  Sahil Kumar 4,  Sumit Dhiman 5,  Utpal Nandi 5,  Rajesh P Ringe 4,  Krishan G Thakur 2 3,  Vinod D Chaudhari 1 2
Affiliations

Affiliations

  • 1 Division of Medicinal Chemistry, Council of Scientific and Industrial Research-Institute of Microbial Technology (CSIR-IMTECH), Sector-39, Chandigarh 160036, India.
  • 2 Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
  • 3 Structural Biology Lab, Council of Scientific and Industrial Research-Institute of Microbial Technology (CSIR-IMTECH), Sector-39, Chandigarh 160036, India.
  • 4 Virology Lab, Council of Scientific and Industrial Research-Institute of Microbial Technology (CSIR-IMTECH), Sector-39, Chandigarh 160036, India.
  • 5 Council of Scientific and Industrial Research-Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu 180001, India.
PMID: 41972862 DOI: 10.1021/acs.jmedchem.6c00365
Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of the 2019 global pandemic, continues to undermine therapeutic interventions due to its high transmissibility and mutability. This highlights the need for potent antivirals capable of combating emerging variants and controlling outbreaks. Here, we report the discovery and development of the first-in-class novel benzimidazole (BZ) derivatives as potent inhibitors of SARS-CoV-2. Through Antiviral screening, the benzimidazolone derivative (I) was found as the hit. Further hit-to-lead optimization led to BZ compounds with submicromolar IC50 values. Mechanistically, these compounds partially inhibit endocytosis entry pathways. The compounds shortlisted have broad-spectrum Antiviral profiles against different variants of concern. Notably, BZ-01 and BZ-30 show good pharmacokinetic properties, with BZ-30 displaying excellent oral bioavailability. Evaluation of BZ-30 in SARS-CoV-2-challenged hamsters significantly reduced viral load and improved lung pathology, indicating its in vivo Antiviral efficacy and highlighting its therapeutic potential as an orally available Antiviral candidate.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-183185
    SARS-CoV-2抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z